perbandingan kadar serum vegf dan mmp-9 pada pasien gastritis h. pylori dan non h. pylori

Teks penuh

(1)

153 DAFTAR PUSTAKA

1. Djojoningrat D. Dispepsia Fungsional. Dalam: Sudoyo AW, editor. Buku ajar Ilmu Penyakit Dalam. Jilid I edisi IV. Jakarta: BP FKUI; 2006. hlm. 354-6.

2. El-Zimaity HMT. Recent advances in the histopathology of gastritis. Current Diagnostic Pathology. 2007;13:340-8.

3. Rugge M, Genta RM. Staging and grading of chronic gastritis. Human pathology. 2005;36:228-33.

4. Fox JG, Megraud F. Helicobacter. In: Murray PR, editor. Manual of clinical microbiology. 9th ed. Pensylvania: Elsevier Mosby; 2007. hlm.947-62.

5. Cesar ACG, Cury PM, Payao SLM. Comparison of histological and molecular diagnosis of Helicobacter pylori in benign lesions and gastric adenocarcinoma. Braz J Microbiol. 2005;36(1):261-6.

6. Banerjee A, Mukhopadhyay AK, Paul S, Bhattacharyya A and Swarnakar S. Unveiling the Intricacies of Helicobacter pylori-induced Gastric Inflammation: T Helper cells and Matrix Metalloproteinases at a Crossroad. In: Mozsik G, editor. Current Topics in Gastritis. Croatia: InTech Publishers; 2013. Chapter 7.

7. Rehnberg-Laiho L, Rautelin H, Koskela P, Sarna S, Pukkala E, Aromaa A, et al. Decreasing prevalence of helicobacter antibodies in Finland, with reference to the decreasing incidence of gastric cancer. Epidemiol Infect. 2001;126:37-42.

8. Matsukura N, Yamada S, Kato S, Tomtitchong P, Tajiri T, Miki M, et al. Genetic differences in interleukin-1 betapolymorphisms among four Asian populations: an analysis of the Asian paradox between H. pylori infection and gastric cancer incidence. J Exp Clin Cancer Res. 2003; 22: 47-55.

9. Tahara T, Arisawa T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, et al. Effect of Polymorphisms in the 3’-Untranslated Region (3’-UTR) of VEGF Gene on Gastric Premalignant Condition. Anticancer research. 2009; 29:458-90.

10.

the gastric mucosa and serum concentration of chosen growth factors in children.

11. Tarnawski AS, Chai J, Jones MK. Esophageal and Gastrointestinal Microcirculation: Essential for Mucosal Protection, a Target for Injury, and a Critical Component of Injury and Ulcer Healing. In: Ishii H, Suematsu M, Tanishita K, editor. Organ microcirculation: a gateway to diagnostic and therapeutic intervention. Tokyo: Springer; 2005. Hlm 49-61. 12. Koskensalo S, Mrena J, Wiksten JP, Nordling S, Kokkola A, Hagstrom J, et al. MMP-7

overexpression is an independent prognostic marker in gastric cancer. Tumor Biol. (2010) 31: 149-155

(2)

154 14. Caruso R, Fina D, Peluso I, Tosti C, Blanco GDV, et al. IL-21Is Highly Produced in

Helicobacter pylori- Infected Gastritis Mucosa and Promotes Gelatinases Synthesis J Immunol 2007;178: 5957-5965

15. Zhang Qiong-Wen, Liu Lei, Chen Ru, Wei Quan, Li Ping, Shi Hua-Shan, Zhao Yu-Wei.: Matrix Metalloproteinase-9 as a Prognostic Factor in Gastric Cancer: A Meta-Analysis. Asian Pacific Journal of Prevention,vol 13,2012. P 2903-2908

16. Hirlan, Gastritis dalam Buku Ajar Ilmu Penyakit Dalam Edisi 5, Internal Publishing : 2009 ; 509-512

17. Pratomo BW. Gastritis dan gastropati dalam buku ajar gastroenterologi. Edisi I. Internal publishing. 2011:307-311

18. S Iiyas. Repository.usu.ac.id.2013

19. Mayo clinic. Gastritis.2014 [diunduh 20 Maret 2015]. Tersedia dari :

20. Wehbi M. Acute gastritis. Medscape. 2014

21. Rugge M, Pennelli G, Pilozzi E, Fassan M, Ingravallo G, Russo VM, et al. Gastritis: the histology report. Digestive and Liver Disease. 2011; 43S:S373–84.

22. Adibi P. Gastritis. [Diunduh 19 Mei 2015]. Tersedia dari:

23. Szoke D. Genetic factors related to the histological and macroscopic lesions of the stomach. [disertasi]. Budapest: Semmelweis University; 2009. Hlm 7-61.

24. Toljamo K. Gastric erosions – clinical significance and pathology. A long-term follow-up study. University of Oulu, Finland:Acta Univ Oul; 2012.hlm 1-80.

25. Zakaria Z. The role of interleukin-10 in Helicobacter pylori infection. Master [Tesis]. Nottingham,UK: University of Nottingham; 2010.hlm. 55.

26. Adam B, et al. Cellular immune activation and clinical manifestation of funcional dyspepsia. Z Gastroenterol 2008;46-v26

27. Elseweidy MM. Helicobacter pylori ifection and its relevant to chronic gastritis. INTECH.2013.http://dx.doi.org/105772/46056

28. Conteduca vincenza, domenico sansonno, gianfranco lauletta, sabino russi, giuseppe ingravallo and franco dammacco. H. pylori infection and gastric cancer: State of the art. international journal of oncology. 2013.42: 5-18.

29. D W, Chey, C B, Wong. American college of gastroenterology guidline on the management of H.pylori infetion. Am J Gastroenterol 2007;102:1808-1825

30. Lew E. Peptic ulcer disease. In: Greenberger NJ, editor. Current Diagnosis and Treatment Gastroenterology, Hepatology, and Endoscopy. New York: McGraw Hill; 2009.hlm.175-83.

31. Simadibrata M. Dyspepsia and Gastroesophageal Reflux Disease (GERD): Is There Any Correlation. Acta Med Indones. 2009; 41(4): 222-7.

32. Silva MIG, de Sousa FCF. Gastric ulcer etiology. In: Chai J, editor. Peptic Ulcer Disease. Shanghai: Intech; 2011.pp.3-28.

33. Syam AF, Sadikin M, Wanandi SI, Rani AA. Molecular mechanism on healing process of peptic ulcer. Acta Med Indones. 2009;41(2):95-8.

(3)

155 35. Cheung R, Cheng TT, Dong Y, Lin HY, Lai K, Lau CS, et al. 2010. Incidence of

gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. Int J Rheum Dis;13(2): 151–7.

36. Wallace JB. Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn’t the Stomach Digest Itself. American Physiological Society. Physiol Rev 88: 1547-1565, 2008.

37. Jośko Jadwiga, Bolesław Gwozdz, Halina Jędrzejowska-Szypułka, Stanisław Hendryk. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Med Sci Monit 2000; 6(5): RA1047-1052

38. Rosen Lee S. Clinical Experience With Angiogenesis Signaling Inhibitors: Focus on Vascular Endothelial Growth Factor (VEGF) Blockers. Cancer Control. March/April 2002, Vol.9, No.2 Supplement

39.

and anti‐angiogenic strategies. Math Med Biol (2003) 20 (2): 135-181

40.

growth and angiogenesis

41.

of Dermatological Scien

42. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The protein data bank. Nucleic acids research 2000; 28: 235-42.

43. Mesiano, S.,Ferrara.,et al. (1998). Role of Vascular Endothelial Growth Factor in Ovarian Cancer.Am J Pathol. 153:1249-1256.

44. Tortora,G., Ciardiello,F. (2004). Angiogenesis : A Target for Cancer Therapy. Current Pharmaceutical Design. 10:11-26

45. Harapan, Permata, 2010, Vascular Endothelial Growth Factor ( VEGF ). Indocancer,

Pusat Informasi Cancer.

2015)

46. Hicklin DJ, Ellis LM. VEGF expression in colorectal cancer. J. Clin Oncol. 2005;23(8):1011-27.

47. Zheng Huachuan, Takahashi Hiroyuki, Murai Yoshihiro, Cui Zhengguo, Nomoto Kazuhiro, Niwa Hideki, Tsuneyama Koichi, Takano Yasuo. Expressions of MMP-2, MMP-9 and VEGF are Closely Linked to Growth, Invasion, Metastasis and Angiogenesis of Gastric Carcinoma Anticancer Research, 2006; 26: 3579-3584.

48. Goren HG, Soker S, Vlodavsky I, Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem. 1992;267(9): 6093-8.

49. Ryu, J.K. 2008. Therapeutic Angiogenesis: The Pros and Cons and the Future. Korean Circ J , 38:73-9.

50. Choi Kyu-Sil, Bae Moon-Kyoung, Jeong Joo-Won, Moon Hyo-Eun and Kim Kyu-Won. Hypoxia-induced Angiogenesis during Carsinogenesis. Journal of Biochemistry and Molecular Biology. 2003. Vol. 36 No.1.pp.120-127

(4)

156 52. Jones MK, Itani RM,Wang H, et al. Activation of VEGF and Ras genes in gastric mucosa

during angiogenic response to ethanol injury. Am J Physiol. 1999a;276:G1345–55. 53. Fornai M, Antonioli L, Colucci R, Tuccori M, Blandizzi C. Pathophysiology of gastric

ulcer development and healing: molecular mechanism and novel therapeutic options. In: Chai J, editor. Peptic Ulcer Disease. Shanghai: Intech; 2011. hlm. 113-42.

54. Jones MK, Tomikawa M, Mohajer B, Tarnawski AS. Gastrointestinal mucosal regeneration: role of growth factors. Frontiers in Bioscience. 1999b;4:303-9.

55. Brzozowski T, Konturek PC, Konturek SJ, Brzozowska I, Pawlik T. Role of prostaglandins in gastroprotection and gastric adaptation. Journal of physiology and pharmacology. 2005; 56(Suppl 3):33-55.

56.

angiogenic switch during carcinogenesis 57. Tarnawski AS, Chai J, Jones MK. Esophageal and Gastrointestinal Microcirculation:

Essential for Mucosal Protection, a Target for Injury, and a Critical Component of Injury and Ulcer Healing. In: Ishii H, Suematsu M, Tanishita K, editor. Organ microcirculation: a gateway to diagnostic and therapeutic intervention. Tokyo: Springer; 2005. Hlm 49-61. 58. Caputo R, Tuccillo C, Manzo BA, Zarrilli R, Tortora G, Blanco CDV, et al. Helicobacter

pylori VacA Toxin Up-Regulates Vascular Endothelial Growth Factor Expression in MKN 28 Gastric Cells through an Epidermal Growth Factor Receptor-, Cyclooxygenase-2-dependent Mechanism. Clin Cancer Res. 2003;9:2015-21.

59. Mueller A, Merrel DS, Grimm J, Falkow S. Profiling of microdissected gastric epithelial cells reveals a cell-type specific response to Helicobacter pylori infection. Gastroenterology. 2004;127:1446–62.

60. Strowski MZ, Cramer T, Schafer G, Juttner S, Walduck A, Schipani E, et al. Helicobacter pylori stimulates host vascular endothelial growth factor-A (vegf-A) gene expression via MERK/ERK-dependent activation of Sp1 and Sp3. FASEB J. 2004;18:218–20.

61. Stein Markus, Paolo Ruggiero, Rino Rappuoli and Fabio Bagnoli et al. Helicobacter pylori CagA: from pathogenic mechanisms to its use as an anti-cancer vaccine. Frontier in immunology. doi: 10.3389/fimmu.2013.00328

62. Mairi Macarthur, Georgina L. Hold, and Emad M. El-Omar. 2004. Inflammation and Cancer. II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 286: G515-G520, 2004; 10.1152/ajpgi.00475.2003.

63. Tarnawski AS, Chai J, Jones MK. Esophageal and Gastrointestinal Microcirculation: Essential for Mucosal Protection, a Target for Injury, and a Critical Component of Injury and Ulcer Healing. In: Ishii H, Suematsu M, Tanishita K, editor. Organ microcirculation: a gateway to diagnostic and therapeutic intervention. Tokyo: Springer; 2005. Hlm 49-61.

64. John. 2006. VEGF Pathwa

65. Blood vessel overgrowth on cell. About lung cancer

2015)

(5)

157 67. Kriskova S, Zitka O, Masarik M et al. Clinical Importance of matrix metalloproteinases.

Bratisl Lek Listy 2011;112(8):435-440

68. Amalinei C, Caruntu ID, Giusca SE et all. Matrix metalloproteinases involvement in pathologic conditions. Romanian Journal of Morphology and Embryology 2010, 51(2):215–228

69. Verma RP,

functions and (Q)SARs.

March 2007, Pages 2223–2268.

70. Angulo JC

cancer using real-time RT-PCR for gelatinases (MMP-2, MMP-9) and TIMP-2 in

peripheral bl

2011,127–136.

71.

Epithelial-to-Mesenchymal Transition in Prostate Cancer. The Journal Of Biological Chemistry. VOL. 283, NO. 10, pp. 6232–6240, March 7, 2008

72. Decocks J, Paridaens R, Ye S. Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clinical Genetics, An International Journal of Genetics, Molecular and Personalized Medicine March 2008

73. Amalinei C, Caruntu ID, Balan RA. Biology of metalloproteinases. Romanian Journal of Morphology and Embryology 2007, 48(4):323–334

74. Charoenrat PO, Rhys-Evans PH, Eccles SA. Expression of Matrix Metalloproteinases and Their Inhibitors Correlates With Invasion and Metastasis in Squamous Cell Carcinoma of the Head and Neck. Arch Otolaryngol Head Neck Surg. 2001;127(7):813-820

75. Rundhaug Joyce E. Matrix Metalloproteinases, Angiogenesis, and Cancer. Clinical Cancer Research February 2003, Vol. 9, 551–554.

76. Hsiu-Chi Cheng, Hsiao-Bai Yang, Wei-Lun Chang, Wei-Ying Chen, Yi-Chun Yeh, and Bor-Shyang Sheu. Expressions of MMPs and TIMP-1 in Gastric Ulcers May Differentiate H. pylori -Infected from NSAID-Related Ulcers. The Scientific World Journal. Volume 2012, Article ID 539316, 9 pages.

77. F.J.G.M. Kubben, C.F.M. Sier, M. Schram, A.M.C. Witte1, R.A. Veenendaal, W. van Duijn, J.H. Verheijen, R. Hanemaaijer, C.B.H.W. Lamers, H.W. Verspaget. Eradication of Helicobacter pylori infection favourably a ects altered gastric mucosal MMP-9 levels. TNO Quality of Life, Biomedical Research, Leiden, The Netherlands. Chapter 3. Helicobacter 2007, in press

78. Musumba C, Pritchard DM, Primohamed M : Cellular and molecular mechanisms of NSAID-induces peptic ulcers. Alimentary Pharmacology and Therapeutics 30,2009. Blackwell Publishing . p517-531

79. Detrick, B., C. Nagineni, and J. Hooks, Cytokines: Regulators of Immune Responses and Key Therapeutic Targets In: MRGOGaAD Donnenberg. Human Immunology, CRC Press, Taylor & Francis Group, 2008: p. 495-516

80. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer 2002:161-174.

81.

Protein in Urinary Bladder Cancer: A Marker of Favorable Prognosis. Anticancer Research 2008. 28: 1757-1762

(6)

158

83.

expression in colorectal tumors from Iraqi patients. Indian Journal of Pathology & Microbiology.2011, Vol.54,Issue:1,pp:7-14

84. Davies B, Waxman J, Wasan H. Levels of Matrix Metalloproteases in Bladder Cancer Correlate with Tumor Grade and Invasion. Cancer Research 1993.5365-5369.

85. Delektorskaya VV, Perevoshehikov AG, Golovkov DA, Kushlinskii NE. Prognostic significance of expression of matric metalloproteinase in colorectal adenocarsinomas and their metastases. Bulletin of experimental biology and medicine. 2007.Vol.143.No.4.pp.434-437

86. Ikebe T, Shinohara M, Takeuchi H et al. Gelatinolytic of matric metalloproteinase in tumor tissue corelates with the invasiveness of oral cancer. Clinical Experimental Metastase 1999(17)pp.315-323.

87. Jasti S. Rao. Molecular mechanisms of glioma invasiveness: the role of proteases. Nature Reviews Cancer 2003.3,pp.489-501

88. Zheng Huachuan, Takahashi Hiroyuki, Murai Yoshihiro, Cui Zhengguo, Nomoto Kazuhiro, Niwa Hideki, Tsuneyama Koichi, Takano Yasuo. Expressions of MMP-2, MMP-9 and VEGF are Closely Linked to Growth, Invasion, Metastasis and Angiogenesis of Gastric Carcinoma. Anticancer Research, 2006; 26: 3579-3584.

89. Bunn Paul A. Jr. Molecularly Targeted Therapies and the Future of Managing SCLC, The Biology of Lung Cancer (MMPs facilitate Angiogenesis).

90. Kurt Atilla, Yanar Fatih, Asoglu Oktar, Balik Emre, Olgac Vakur, Karanlik Hasan, Kucuk Sevda Tanrikulu, Ademoglu Evin, Yegen Gulcin and Bugra Dursun. Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation. BMC Clinical Pathology 2012,12:27.

91. Chen H, Ying L, Kong M, Zhang Y, Li Y. The Prevalence of Helicobacter pylori Infection Decreases with Older Age in Atrophic Gastritis. Gastroenterology Research and Practice. 2013:Aug;21(2

92. Betty. Infeksi Helicobacter pylori pada lesi gastritis yang didiagnosa dengan Pewarnaan Histokimia Giemsa dan Imunohistokimia Helicobacter pylori di Laboratorium Patologi

Anatomi Fakultas Kedokteran USU Medan. 2012.

93. Parameswaran I, Hubungan peningkatan kadar leukosit dan neutropil dengan infeksi H.pylori di RSU Permata Bunda Medan.2014.

94. Zho Y, et al. Risk factors and prevalence of H.Pylori infection in persistent high

incidence area of gastric carcinoma in Yangzhong city.2014.

95. Naja F,et al. Helicobacter pylori in Ontario : prevalence and rsik factors.Jurnal canadian of gastroenterologi. 2007:21(8):501-506

96. Abidiev S, Ahn KS, Khadjibaev A, Malikov Y, Bahramov S, Rakhimov B, et al. Helicobacter pylori infection and cytokine gene polymorphisms in Uzbeks. Nagoya J Med Sci, 2010;72:167-72

(7)

159 98. Musumba C, Pritchard DM, Primohamed M : Cellular and molecular mechanisms of

NSAID-induces peptic ulcers. Alimentary Pharmacology and Therapeutics 30,2009. Blackwell Publishing . p517-531

99. Detrick, B., C. Nagineni, and J. Hooks, Cytokines: Regulators of Immune Responses and Key Therapeutic Targets In: MRGOGaAD Donnenberg. Human Immunology, CRC Press, Taylor & Francis Group, 2008: p. 495-516

100. Sen Lin Li, Jing Run Zhao, Xiao Yan Ren, Jia Ping Xie, Qing Zhu Ma, Qiu Hua Rong. Increased expression of matrix metalloproteinase-9 assosiated with gastric ulcer recurren. World J Gastroenterol 2013;(28)19:4590-5.

101. Dongping Liu, Qingjuan He, Caigang Liu. Correlation among Helicobacter pylori infection and the expression of cyclooxygenase-2 and vascular endhotelial growth factor in gastric mucosa with intestinal metaplasia or dysplasia. J Gastroenterol Hepatol 2010;(25)4:795-9.

102. Wu CY, Wang CJ, Tseng CC, Chen HP, Wu MS, Lin JT, Inoue H, Chen GH. Helicobacter pylori promote gastric cancer cells invasion through a NF-kappaB and COX-2-mediated pathway. World J Gastroenterol, 2005;11(21):3197-203.

103. OU Yurong, Kang Min, Zhou Lei, Cheng Zenong, Tang Sulan, Yu Donghong. Infection with L-form of Helicobacter pylori and exspression of MIF, MMP-9 and VEGF in gastric carsinoma. Nan Fang Yi Ke Da Xue Xue Bao.2014;34(2):180-7.

104. Yan Feng Liu, Sen Guo, Rui Zhao, Yue Guang Chen, Xian qiang Waang, Ke Sen Xu. Correlation of Vascular Endotelial Growth Factor Expression With Tumor Recurrence and Poor Prognosis in Patients With pN0 Gastric Cancer. World J Surg.2012;36(1):109-17.

105. Adam B, et al. Cellular immune activation and clinical manifestation of funcional dyspepsia. Z Gastroenterol 2008;46-v26

Figur

Memperbarui...

Referensi

Memperbarui...